Journal of Hepatocellular Carcinoma
Volume 10, 2023 - Issue
ORIGINAL RESEARCH
Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
Jingzhong Ouyang1 Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, People’s Republic of China
https://orcid.org/0000-0002-3398-6465View further author information
https://orcid.org/0000-0002-3398-6465View further author information, , Kun Yuan2 School of Public Health, Capital Medical University, Beijing, People’s Republic of Chinahttps://orcid.org/0000-0002-0225-9214View further author information
https://orcid.org/0000-0002-0225-9214View further author information, Yi Yang3 Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China;4 Key Laboratory of Gene Editing Screening and Research and Development (R&D) of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of Chinahttps://orcid.org/0000-0002-9835-4098View further author information
https://orcid.org/0000-0002-9835-4098View further author information, , Qingjun Li1 Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, People’s Republic of Chinahttps://orcid.org/0000-0001-5650-795XView further author information
https://orcid.org/0000-0001-5650-795XView further author information, , , Hong Zhao3 Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China;4 Key Laboratory of Gene Editing Screening and Research and Development (R&D) of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-6063-2099View further author information
https://orcid.org/0000-0002-6063-2099View further author information & show all